| __timestamp | Alnylam Pharmaceuticals, Inc. | Biogen Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 2232342000 |
| Thursday, January 1, 2015 | 60610000 | 2113100000 |
| Friday, January 1, 2016 | 89354000 | 1947900000 |
| Sunday, January 1, 2017 | 199365000 | 1935500000 |
| Monday, January 1, 2018 | 382359000 | 2106300000 |
| Tuesday, January 1, 2019 | 479005000 | 2374700000 |
| Wednesday, January 1, 2020 | 588420000 | 2504500000 |
| Friday, January 1, 2021 | 620639000 | 2674300000 |
| Saturday, January 1, 2022 | 770658000 | 2403600000 |
| Sunday, January 1, 2023 | 795646000 | 2549700000 |
| Monday, January 1, 2024 | 975526000 | 2403700000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Alnylam Pharmaceuticals and Biogen Inc., two giants in the industry, have shown contrasting approaches over the past decade. From 2014 to 2023, Biogen consistently maintained higher SG&A expenses, peaking at approximately $2.67 billion in 2021. In contrast, Alnylam's SG&A costs grew steadily, reaching around $796 million in 2023, marking an increase of over 1,600% from 2014. This stark difference highlights Biogen's expansive operational scale compared to Alnylam's more conservative growth strategy. While Biogen's larger expenses reflect its extensive market reach, Alnylam's rapid increase suggests aggressive expansion efforts. Understanding these trends offers valuable insights into each company's strategic priorities and operational efficiencies.
Cost Management Insights: SG&A Expenses for Merck & Co., Inc. and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights
Alnylam Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.
Biogen Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Biogen Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Biogen Inc. and Taro Pharmaceutical Industries Ltd.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Biogen Inc. vs Novavax, Inc.
Biogen Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared